Market capitalization | $12.63b |
Enterprise Value | $12.31b |
P/E (TTM) P/E ratio | 39.90 |
EV/FCF (TTM) EV/FCF | 38.48 |
EV/Sales (TTM) EV/Sales | 4.48 |
P/S ratio (TTM) P/S ratio | 4.60 |
P/B ratio (TTM) P/B ratio | 2.33 |
Revenue growth (TTM) Revenue growth | 19.99% |
Revenue (TTM) Revenue | $2.75b |
As a Free StocksGuide user, you can view scores for all 6,889 stocks worldwide.
30 Analysts have issued a Biomarin Pharmaceutical forecast:
30 Analysts have issued a Biomarin Pharmaceutical forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,747 2,747 |
20%
20%
|
|
Gross Profit | 2,118 2,118 |
23%
23%
|
|
EBITDA | 490 490 |
128%
128%
|
EBIT (Operating Income) EBIT | 391 391 |
246%
246%
|
Net Profit | 322 322 |
119%
119%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
Head office | United States |
CEO | Alexander Hardy |
Employees | 3,401 |
Founded | 1997 |
Website | www.biomarin.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.